| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J63-008 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6857
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6885
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6911
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6855
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6817
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6845
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6807
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-643
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-593
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-595
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J63-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-642 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 |
| filingDate |
2019-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2022516045-A |
| titleOfInvention |
Saponins conjugated to epitope-binding proteins |
| abstract |
【wrap up】 The present invention relates to a combination of therapeutic agents and comprises a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell surface molecule (the first proteinaceous molecule is described above. A second pharmaceutical composition comprising a second proteinaceous molecule that is covalently bound to the amino acid residue of the first proteinaceous molecule) and that is different from the first proteinaceous molecule. The second proteinaceous molecule comprises and contains a second binding site for binding to a second epitope of a second cell surface molecule that is different from the first cell surface molecule and comprises an effector moiety. The epitope of is different from the first epitope. One embodiment of the present invention is a composition comprising a first proteinaceous molecule and a second proteinaceous molecule of the present invention. The invention also relates to antibody-drug conjugates comprising the first proteinaceous molecule and effector moieties of the invention. One aspect of the invention relates to the composition of the invention or a pharmaceutical composition comprising an antibody-drug conjugate and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to combinations or compositions of the therapeutic agents of the invention, or antibody-drug conjugates, or pharmaceutical compositions for use as pharmaceuticals. The invention also relates to a combination of therapeutic agents of the invention for use in the treatment or prevention of cancer. |
| priorityDate |
2018-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |